OBJECTIVE  To observe the effect of ginger moxibustion combined with Adalimumab on the mood and life quality of patients with anxiety and Crohn's disease at mild and moderate active stages.

  METHODS  60 patients with anxiety and Crohn's disease at mild and moderate active stages who met the inclusion criteria were selected and randomly divided into the treatment group and control group with 30 cases each.The control group was given a standardized treatment of Adalimumab, and the treatment group was treated with ginger moxibustion on the basis of the control group.The course of treatment was 12 weeks.Observe the changes in TCM syndrome score and clinical efficacy, anxiety relief response rate, Crohn's disease activity index (CDAI) score, Inflammatory bowel disease quality of life (IBDQ) score, and safety indicators of the two groups of patients before and after treatment.

  RESULTS  After treatment, the TCM syndrome scores of both groups were significantly reduced (P < 0.05, P < 0.01), and the treatment group was superior to the control group (P < 0.05, P < 0.01);the clinical efficacy and anxiety relief response rate of the treatment group were better than those of the control group (P < 0.05);the IBDQ scores of both groups were significantly increased (P < 0.05, P < 0.01), and the treatment group was better than the control group (P < 0.05);the CDAI scores of both groups significantly decreased (P < 0.05, P < 0.01), and the treatment group was better than the control group (P < 0.05, P < 0.01).

  CONCLUSION  Ginger moxibustion combined with Adalimumab can improve the anxiety and life quality of patients with Crohn's disease at mild and moderate active stages.